# Tectonic Therapeutic, Inc.: financial statements, quarterly

TECX · Nasdaq · CIK 1681087 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tecx.md) · [Financials](/companies/tecx/financials.md) · [Filings](/companies/tecx/filings.md) · [Insiders](/companies/tecx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tecx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [8.1](/filings/0000950170-24-125304.md) | [7.2 d](/filings/0000950170-25-042648.md) | [10.8](/filings/0000950170-25-067037.md) | [7.1](/filings/0000950170-25-104974.md) | [14.3](/filings/0001193125-25-269701.md) | [9.2 d](/filings/0001193125-26-076793.md) | [13.0](/filings/0001193125-26-212016.md) | [17.2](/filings/0001193125-26-338062.md) | [16.9](/filings/0001193125-25-269701.md) | [16.3 d](/filings/0001193125-26-076793.md) | [20.9](/filings/0001193125-26-212016.md) | [18.0](/filings/0001193125-26-338062.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | [9.9](/filings/0001193125-24-200609.md) | [0.0 d](/filings/0000950170-24-125304.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(10.1)](/filings/0000950170-24-125304.md) | [(9.4) d](/filings/0000950170-25-042648.md) | [(13.0)](/filings/0000950170-25-067037.md) | [(11.4)](/filings/0000950170-25-104974.md) | [(19.6)](/filings/0001193125-25-269701.md) | [(14.0) d](/filings/0001193125-26-076793.md) | [(18.3)](/filings/0001193125-26-212016.md) | [(22.3)](/filings/0001193125-26-338062.md) | [(21.9)](/filings/0001193125-25-269701.md) | [(21.5) d](/filings/0001193125-26-076793.md) | [(27.3)](/filings/0001193125-26-212016.md) | [(24.2)](/filings/0001193125-26-338062.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-125304.md) | [0.0 d](/filings/0000950170-25-042648.md) | [0.0](/filings/0000950170-25-067037.md) | [0.0](/filings/0000950170-25-104974.md) | [0.0](/filings/0001193125-25-269701.md) | [0.0 d](/filings/0001193125-26-076793.md) | [0.0](/filings/0001193125-26-212016.md) | [0.0](/filings/0001193125-26-338062.md) | [0.0](/filings/0001193125-25-269701.md) | [0.0 d](/filings/0001193125-26-076793.md) | [0.0](/filings/0001193125-26-212016.md) | [0.0](/filings/0001193125-26-338062.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-125304.md) | [0.0 d](/filings/0000950170-25-042648.md) | not reported | [0.0](/filings/0000950170-25-104974.md) | [0.0](/filings/0001193125-25-269701.md) | [0.0 d](/filings/0001193125-26-076793.md) | not reported | [1.0](/filings/0001193125-26-338062.md) | [0.0](/filings/0001193125-25-269701.md) | [0.3 d](/filings/0001193125-26-076793.md) | not reported | [0.1](/filings/0001193125-26-338062.md) |
| Net income | $m | [(10.1)](/filings/0000950170-24-125304.md) | [(7.9) d](/filings/0000950170-25-042648.md) | [(15.2)](/filings/0001193125-25-269701.md) | [(12.7)](/filings/0001193125-25-269701.md) | [(17.7)](/filings/0001193125-25-269701.md) | [(12.4) d](/filings/0001193125-26-076793.md) | [(15.9)](/filings/0001193125-26-338062.md) | [(20.0)](/filings/0001193125-26-338062.md) | [(19.0)](/filings/0001193125-25-269701.md) | [(19.2) d](/filings/0001193125-26-076793.md) | [(25.2)](/filings/0001193125-26-338062.md) | [(22.3)](/filings/0001193125-26-338062.md) |
| Diluted EPS | $ per share | [(7.62)](/filings/0000950170-24-125304.md) | not reported | [(10.97)](/filings/0000950170-25-067037.md) | [(4.34)](/filings/0000950170-25-104974.md) | [(1.20)](/filings/0001193125-25-269701.md) | not reported | [(0.93)](/filings/0001193125-26-212016.md) | [(1.07)](/filings/0001193125-26-338062.md) | [(1.02)](/filings/0001193125-25-269701.md) | not reported | [(1.34)](/filings/0001193125-26-212016.md) | [(1.18)](/filings/0001193125-26-338062.md) |
| Basic EPS | $ per share | [(7.62)](/filings/0000950170-24-125304.md) | not reported | [(10.97)](/filings/0000950170-25-067037.md) | [(4.34)](/filings/0000950170-25-104974.md) | [(1.20)](/filings/0001193125-25-269701.md) | not reported | [(0.93)](/filings/0001193125-26-212016.md) | [(1.07)](/filings/0001193125-26-338062.md) | [(1.02)](/filings/0001193125-25-269701.md) | not reported | [(1.34)](/filings/0001193125-26-212016.md) | [(1.18)](/filings/0001193125-26-338062.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.3](/filings/0000950170-24-125304.md) | [28.8](/filings/0000950170-25-042648.md) | [18.7](/filings/0000950170-25-067037.md) | [185](/filings/0000950170-25-104974.md) | [159](/filings/0001193125-25-269701.md) | [141](/filings/0001193125-26-076793.md) | [306](/filings/0001193125-26-212016.md) | [287](/filings/0001193125-26-338062.md) | [268](/filings/0001193125-25-269701.md) | [254](/filings/0001193125-26-338062.md) | [237](/filings/0001193125-26-212016.md) | [227](/filings/0001193125-26-338062.md) |
| Current assets | $m | [109](/filings/0000950170-23-062131.md) | [30.9](/filings/0000950170-25-042648.md) | [91.8](/filings/0000950170-24-057091.md) | [187](/filings/0001193125-24-200609.md) | [163](/filings/0000950170-24-125304.md) | [147](/filings/0001193125-26-076793.md) | [310](/filings/0000950170-25-067037.md) | [291](/filings/0000950170-25-104974.md) | [273](/filings/0001193125-25-269701.md) | [257](/filings/0001193125-26-338062.md) | [240](/filings/0001193125-26-212016.md) | [231](/filings/0001193125-26-338062.md) |
| Total assets | $m | [111](/filings/0000950170-23-062131.md) | [39.4](/filings/0000950170-25-042648.md) | [92.3](/filings/0000950170-24-057091.md) | [194](/filings/0001193125-24-200609.md) | [169](/filings/0000950170-24-125304.md) | [153](/filings/0001193125-26-076793.md) | [315](/filings/0000950170-25-067037.md) | [295](/filings/0000950170-25-104974.md) | [277](/filings/0001193125-25-269701.md) | [261](/filings/0001193125-26-338062.md) | [247](/filings/0001193125-26-212016.md) | [237](/filings/0001193125-26-338062.md) |
| Current liabilities | $m | [7.6](/filings/0000950170-23-062131.md) | [40.9](/filings/0000950170-25-042648.md) | [3.5](/filings/0000950170-24-057091.md) | [26.0](/filings/0001193125-24-200609.md) | [17.3](/filings/0000950170-24-125304.md) | [11.6](/filings/0001193125-26-076793.md) | [13.5](/filings/0000950170-25-067037.md) | [11.4](/filings/0000950170-25-104974.md) | [9.4](/filings/0001193125-25-269701.md) | [9.7](/filings/0001193125-26-338062.md) | [13.0](/filings/0001193125-26-212016.md) | [10.4](/filings/0001193125-26-338062.md) |
| Total liabilities | $m | [7.7](/filings/0000950170-23-062131.md) | [43.4](/filings/0000950170-25-042648.md) | [3.5](/filings/0000950170-24-057091.md) | [27.5](/filings/0001193125-24-200609.md) | [18.4](/filings/0000950170-24-125304.md) | [12.1](/filings/0001193125-26-076793.md) | [13.8](/filings/0000950170-25-067037.md) | [11.5](/filings/0000950170-25-104974.md) | [9.5](/filings/0001193125-25-269701.md) | [9.7](/filings/0001193125-26-338062.md) | [16.2](/filings/0001193125-26-212016.md) | [13.2](/filings/0001193125-26-338062.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(79.8)](/filings/0000950170-24-125304.md) | [(84.6)](/filings/0001193125-26-076793.md) | [(99.6)](/filings/0001193125-25-269701.md) | [166](/filings/0001193125-25-269701.md) | [150](/filings/0001193125-25-269701.md) | [141](/filings/0001193125-26-338062.md) | [301](/filings/0001193125-26-338062.md) | [284](/filings/0001193125-26-338062.md) | [268](/filings/0001193125-25-269701.md) | [251](/filings/0001193125-26-338062.md) | [230](/filings/0001193125-26-338062.md) | [224](/filings/0001193125-26-338062.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.5) d](/filings/0000950170-24-125304.md) | [(11.7) d](/filings/0000950170-25-042648.md) | [(9.3)](/filings/0000950170-25-067037.md) | [(13.4) d](/filings/0000950170-25-104974.md) | [(19.6) d](/filings/0001193125-25-269701.md) | [(16.8) d](/filings/0001193125-26-076793.md) | [(13.1)](/filings/0001193125-26-212016.md) | [(14.7) d](/filings/0001193125-26-338062.md) | [(17.8) d](/filings/0001193125-25-269701.md) | [(14.5) d](/filings/0001193125-26-076793.md) | [(18.4)](/filings/0001193125-26-212016.md) | [(21.5) d](/filings/0001193125-26-338062.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125304.md) | [0.1 d](/filings/0000950170-25-042648.md) | [0.0](/filings/0000950170-25-067037.md) | [(0.0) d](/filings/0000950170-25-104974.md) | [0.2 d](/filings/0001193125-25-269701.md) | [0.0 d](/filings/0001193125-26-076793.md) | [0.0](/filings/0001193125-26-212016.md) | [0.0 d](/filings/0001193125-26-338062.md) | [0.2 d](/filings/0001193125-25-269701.md) | [0.0 d](/filings/0001193125-26-076793.md) | [0.0](/filings/0001193125-26-212016.md) | [0.1 d](/filings/0001193125-26-338062.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.8](/filings/0000950170-23-062131.md) | [44.0](/filings/0000950170-24-057091.md) | [1.2](/filings/0001193125-24-200609.md) | [1.3](/filings/0000950170-24-125304.md) | [1.4](/filings/0000950170-25-067037.md) | [2.9](/filings/0000950170-25-104974.md) | [14.7](/filings/0001193125-25-269701.md) | [17.2](/filings/0001193125-26-212016.md) | [18.7](/filings/0001193125-26-338062.md) | [18.7](/filings/0001193125-25-269701.md) | [18.8](/filings/0001193125-26-212016.md) | [19.0](/filings/0001193125-26-338062.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,549,366 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.